行情

ADVM

ADVM

Adverum
NASDAQ

实时行情|Nasdaq Last Sale

5.78
-0.18
-3.02%
盘前: 5.36 -0.42 -7.27% 08:42 09/16 EDT
开盘
6.07
昨收
5.96
最高
6.13
最低
5.01
成交量
1,169.41万
成交额
--
52周最高
16.38
52周最低
2.620
市值
3.73亿
市盈率(TTM)
-5.5126
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADVM 新闻

  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.5小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.5小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.5小时前
  • 若沙特局势恶化 韩国将考虑释放战略石油储备
  • 新浪财经综合.5小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

ADVM 简况

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
展开

Webull提供Adverum Biotechnologies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。